Anti-infective agents are drugs used for the purpose of killing and/or suppressing the infection causing organisms from invading the host by means of its replication or releasing variety of toxins into the host. Infection causing micro-organisms include bacteria, viruses, fungi, viroids, and macro parasites. Infections thus caused can be classified depending on type of organism causing the infection and symptoms and medical signs shown by the host.
The anti-infective market has been continuously expanding and the pharmaceutical sector generates higher profit margin than any other sector globally. Rise in the number of hospitals and primary care clinics also boosts the demand for anti-infective drugs. Currently, antimicrobial resistance is a major risk factor to the industry and as per the World Health Organization (WHO) last year, 480,000 people develop multi-drug resistance against tuberculosis drugs every year. Similarly, Staphylococcus aureus produces methicillin resistance in various region of the world. This is of paramount concern to the anti-infectives market at the present.
Key drivers of the anti-infective market include increase in the number of patients, new drug introductions, and significant number of vaccines gaining approvals. Rise in resistance of infection causing organisms to the existing drug therapies is anticipated to pose a major challenge to the anti-infective market. Furthermore, high price of drugs, dicey reimbursement policies, and competition between generic manufacturers are expected to hinder the growth of the anti-infective market. The anti-infective market is highly fragmented due to the presence of a large number of domestic and international players. The focus of developing anti-infective agents has shifted to antiviral agents due to requirement of longer treatment regimens in a large number of patients with chronic indications as compared to antibacterial and antifungal agents requiring shorter treatments.
The global anti-infective market can be classified, based on product type, as antifungal, antiviral, and antibacterials. The antibacterials segment can be further divided into macrolides, cephalosporins, carbopenems, penicillins, quinolones, sulfonamides, tetracyclines, and others. Antibacterials is a high revenue generating segment as compared to the other segments due to the high prescription rates of the antibacterial products. The antifungals segment includes azoles, echinocandins, and polyenes.
Geographically, the anti-infective market can be bifurcated into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each geographical market is sub-divided into specific countries such as the U.S., Canada, Germany, the U.K., Brazil, India, Japan, and GCC countries. North America is the dominating region in the anti-infective market due to the well-spread awareness of anti-infectives among end-users such as health care professionals and clinicians and the presence of developed health care infrastructure in the region. These factors are estimated to drive the anti-infective market in the region during the forecast period. Europe is the next leading region in the anti-infective market. Asia Pacific accounted to be the most prominent region for anti-infectives over the forecast period. India is expected to exhibit high growth potential in terms of demand for anti-infectives due to the presence of a large patient pool, governmental initiatives in undertaking various control programs, and rise in cost containment initiatives by drug manufacturers.
Key players contributing to the growth of the anti-infective market include Abbott Laboratories Limited, Cipla Ltd., Claris Life Sciences Ltd., Glenmark Pharmaceuticals Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Lupin Ltd., Panacea Biotech Ltd., Novartis AG, Pfizer Ltd., Ranbaxy Laboratories Ltd., and Sun Pharmaceutical Industries Ltd. In order to gain competitive advantage in the market, the key players are actively involved in various growth strategies such as agreements, partnerships and collaborations, and new product development.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.